PreciseDx, Inc.
StreetZero Signal 65
About PreciseDx, Inc.
PreciseDx is the developer of PreciseBreast, a novel breast cancer diagnostic powered by its proprietary OncoIntelligence AI platform. The platform analyzes morphology features to deliver patient-specific cancer risk stratification. It has completed analytical and clinical validation studies, received CLIA and CLEP NYSDOH approvals, and established collaborations with institutions including UCLA, Baylor Scott & White Health, and Baptist Health South Florida. The company is planning a 2026 commercial launch of its flagship product.
LATEST FUNDINGPrivate Placement
$3.7M
Announced 2026-10-07
IN THE NEWS
- 🔗 PreciseDx Secures $11M in New Funding
- 🔗 PreciseDx
- 🔗 PreciseDx Continues Path to Commercial Launch: Secures Additional Funding and Announces New Leadership
- 🔗 PreciseDx Raises $10.75 Million Series A Preferred from Healthcare Industry Leaders to Commercialize Cancer Risk Stratification Services to Support Better Patient Insights and Outcomes - Mount Sinai Innovation Partners
- 🔗 Labcorp, Quest Diagnostics back PreciseDx's $20.7M series B
EMPLOYEES—
FOUNDED—
HQNew York, NY, USA
Industry
Other Health Care
Tags
AIDiagnosticsOncologyHealthcare
Investors
Key highlights
- Raised $10.75M Series A in 2021 led by Merck GHI to commercialize AI risk stratification.
- Closed $20.7M Series B led by Eventide with Labcorp and Quest Diagnostics participation.
- Achieved CLIA approval and published Cost Impact Study in Journal of Medical Economics.
- Secured $11M additional funding in 2025 for 2026 PreciseBreast launch.
- Completed analytical and clinical validation studies with collaborations at UCLA and Baylor.
Ask StreetZero about PreciseDx, Inc.
Put our AI to work on this deal.
Similar companies
Other Other Health Care deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account